Blake Schutter Theil Wealth Advisors LLC Acquires Shares of 1,787 iShares Biotechnology ETF (NASDAQ:IBB)

Blake Schutter Theil Wealth Advisors LLC bought a new position in shares of iShares Biotechnology ETF (NASDAQ:IBB) during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 1,787 shares of the financial services provider’s stock, valued at approximately $260,000.

Other institutional investors and hedge funds have also made changes to their positions in the company. Highline Wealth Partners LLC purchased a new position in iShares Biotechnology ETF during the 3rd quarter worth $30,000. Bbjs Financial Advisors LLC purchased a new position in shares of iShares Biotechnology ETF during the second quarter worth about $31,000. Voisard Asset Management Group Inc. purchased a new position in shares of iShares Biotechnology ETF during the third quarter worth about $59,000. Eastern Bank acquired a new position in iShares Biotechnology ETF in the 3rd quarter valued at about $65,000. Finally, Chris Bulman Inc purchased a new stake in iShares Biotechnology ETF during the 2nd quarter valued at approximately $64,000. 62.45% of the stock is owned by hedge funds and other institutional investors.

iShares Biotechnology ETF Trading Up 1.0 %

Shares of IBB stock opened at $148.02 on Friday. The business’s 50 day moving average is $144.83 and its two-hundred day moving average is $140.93. iShares Biotechnology ETF has a twelve month low of $113.56 and a twelve month high of $150.57.

iShares Biotechnology ETF Dividend Announcement

The company also recently disclosed a dividend, which was paid on Monday, September 30th. Investors of record on Wednesday, September 25th were given a $0.2005 dividend. The ex-dividend date of this dividend was Wednesday, September 25th.

iShares Biotechnology ETF Company Profile

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.